The US Food and Drug Administration (FDA) has issued a draft guidance as part of its efforts to encourage drug developers to enroll more patients in clinical trials.

The guidance builds on the earlier efforts by FDA to expand clinical trial eligibility criteria and bring in several underrepresented patient populations into clinical trials.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

FDA draft stated: “This guidance recommends approaches that sponsors of clinical trials to support a new drug application (NDA) or a biologics license application (BLA) can take to broaden eligibility criteria, when scientifically and clinically appropriate, and increase enrollment of underrepresented populations in their clinical trials.”

Some group of patients that are often excluded from trials without strong clinical or scientific justification, include women, the elderly, HIV, etc.

However, by excluding such patients, FDA states that drugmakers are likely to miss key safety signals.

FDA has recommended sponsors to look into each exclusion criteria between Phase II and III studies and remove those criteria that are no longer required for patient safety.

For clinical trials on rare diseases, the guidance offers a separate set of recommendations.

FDA stated: “Traditionally, participants are often ineligible for a phase 3 trial if they had been previously exposed to the drug in an earlier-phase trial; however, with so few participants in rare disease trials, re-enrolling participants may facilitate the analysis of safety and efficacy in the broadest possible population.”

According to the agency, patient participation should be encouraged by ensuring all study participants have access to the investigational treatment.